[1] C. Zhou et al. 7MO - Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial. Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856
[2] Y. Shi et al. 1O - Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG). Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856
[3] C. Lyu et al. 81MO - Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results. Annals of Oncology (2022) 33 (suppl_2): S71-S78. 10.1016/annonc/annonc857
[4] Q. Zhang et al. 86P - Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer. Annals of Oncology (2022) 33 (suppl_2): S71-S78. 10.1016/annonc/annonc857.
[5] M. Tiseo et al. 29P - Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results. Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856
[6] Y. Shi et al. 30P - A phase I, dose-escalation and dose-expansion study of SY-3505: A third-generation ALK TKI in Chinese ALK-positive advanced non-small cell lung cancer. Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856